ArticleScientific reports2025
TLR4 identified as a major depressive disorder gene signature mediating effects through multiple immune cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Metabolomic dysregulation in the association between major depressive disorder and chronic pancreatitis: a large prospective cohort study.Frontiers in nutrition · 2026Article
- TLR4 as a therapeutic target: Antidepressant mechanism of saikosaponin A in regulating the NF-κB/BDNF axis and mitigating oxidative stress and inflammationFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The pathogenesis of major depressive disorder (MDD) is currently unclear and lacks objective diagnostic criteria. The complexity and heterogeneity of MDD also limit precise treatment. Using bioinformatics methods, we identified 18 gene signatures of MDD from the GSE98793 dataset, and validated them in an independent dataset GSE44593 (Area under the curve values were 0.92, 0.72, and 0.70 for the training, validation, and test sets, respectively). Among the gene signatures, TLR4 had the largest absolute coefficient value (coefficient = -6.13). We further identified three CD 14 + monocyte-associated gene signatures and two immune-related subtypes. The expression of TLR4 is significantly increased in subtype A of MDD (lower predicted probability), and is significantly correlated with the composition of multiple immune cells (P < 0.05). We validated that TLR4 acts as a protective factor in MDD (OR = 0.91, 95% CI = 0.85 to 0.98, P = 0.012), and its expression is driven by the same causal variants as MDD (H4/(H3 + H4) = 98.62%). Further analysis showed that the relationship between TLR4 and MDD is influenced by eight immune cell signatures. Our research provided genetic support that the immune factors may play an important role in MDD, and proposed a possible strategy for the diagnosis and treatment of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.